ARTICLE | Clinical News
MG98: BBG plans to start next quarter a Phase I study of a continuous infusion of MG98 over 2 weeks to treat solid tumors in an undisclosed number of patients.
July 15, 2002 7:00 AM UTC
British Biotech plc (LSE:BBG; BBIOY), Oxford, U.K. MethylGene Inc., Montreal, Quebec MGI Pharma Inc. (MOGN), Minneapolis, Minn. Business: Cancer Product: MG98 Therapeutic category: Antisense Descrip...